Novo-Nordisk A/S
US.NVO
46.60
-0.91
-1.92%
Novo-Nordisk A/S
46.60
-0.91
-1.92%
Live - 104 symbols - heartbeat 447s ago
· 2026-09-04 20:02
Pre-market
46.36
-2.42%
After-hours
46.50
-0.21%
Overnight
46.81
-1.47%
Revenue annual, last 8 years
Latest year +6.43% YoY
Margins
- Gross margin
- 80.98%
- Operating margin
- 41.30%
- Net margin
- 33.14%
Key ratios & quality
- Enterprise value
- 304.83B
- PEG ratio
- 0.51
- Altman Z-Score
- 2.11
PEG uses trailing P/E against the 3-year net income growth rate (22.65%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.11, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 111.83B | 122.02B | 126.95B | 140.80B | 176.95B | 232.26B | 290.40B | 309.06B |
| Gross profit | 94.21B | 101.93B | 106.01B | 117.14B | 148.51B | 196.50B | 245.88B | 250.28B |
| Selling & admin expenses | 33.31B | 35.83B | 36.89B | 41.06B | 50.68B | 61.60B | 67.38B | 70.28B |
| Research & development | 14.81B | 14.22B | 15.46B | 17.77B | 24.05B | 32.44B | 48.06B | 52.04B |
| Operating profit | 47.25B | 52.48B | 54.13B | 58.64B | 74.81B | 102.57B | 128.34B | 127.66B |
| Pretax profit | 47.62B | 48.55B | 53.13B | 59.08B | 69.06B | 104.67B | 127.19B | 130.54B |
| Tax | 8.99B | 9.60B | 10.99B | 11.32B | 13.54B | 20.99B | 26.20B | 28.11B |
| Net profit | 38.63B | 38.95B | 42.14B | 47.76B | 55.53B | 83.68B | 100.99B | 102.43B |
| Basic EPS | 8 | 8 | 9 | 10 | 12 | 19 | 23 | 23 |
| Diluted EPS | 7.97 | 8.19 | 9.01 | 10.37 | 12.22 | 18.62 | 22.63 | 23.03 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 78.09B | 76.86B | 74.98B | 79.14B | 96.82B | 78.49B |
| Gross profit | 65.20B | 64.01B | 57.07B | 64.00B | 83.23B | 61.39B |
| Selling & admin expenses | 16.11B | 18.85B | 17.88B | 17.44B | 13.22B | 16.31B |
| Research & development | 10.31B | 11.69B | 15.39B | 14.65B | 10.28B | 17.79B |
| Operating profit | 38.79B | 33.45B | 23.68B | 31.74B | 59.62B | 27.06B |
| Pretax profit | 37.03B | 33.81B | 25.52B | 34.19B | 62.17B | 26.88B |
| Tax | 8.00B | 7.30B | 5.51B | 7.29B | 13.62B | 5.89B |
| Net profit | 29.03B | 26.50B | 20.01B | 26.89B | 48.56B | 20.99B |
| Basic EPS | 7 | 6 | 5 | 6 | 11 | 5 |
| Diluted EPS | 6.53 | 5.96 | 4.50 | 6.04 | 10.91 | 4.74 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 59.07B | 62.46B | 65.81B | 85.60B | 108.19B | 139.65B | 161.79B | 172.45B |
| Cash & ST investments | 15.64B | 15.48B | 12.76B | 17.49B | 23.57B | 30.23B | 26.31B | 26.96B |
| Inventory | 16.34B | 17.64B | 18.54B | 19.62B | 24.39B | 31.81B | 40.85B | 49.62B |
| Total assets | 110.77B | 125.61B | 144.92B | 194.51B | 241.26B | 314.49B | 465.63B | 542.90B |
| Total current liabilities | 54.16B | 58.98B | 70.27B | 99.52B | 120.94B | 169.66B | 217.61B | 215.66B |
| Short-term debt | 515.00M | 1.47B | 7.46B | 13.68B | 1.47B | 6.48B | 13.11B | 12.02B |
| Long-term debt | -- | -- | -- | 9.65B | 20.78B | 15.98B | 84.25B | 111.71B |
| Total liabilities | 58,930,000,000.00 | 68,019,000,000.00 | 81,597,000,000.00 | 123,762,000,000.00 | 157,771,000,000.00 | 207,925,000,000.00 | 322,144,000,000.00 | 348,855,000,000.00 |
| Total equity | 51.84B | 57.59B | 63.33B | 70.75B | 83.49B | 106.56B | 143.49B | 194.05B |
| Retained earnings | 53.41B | 57.82B | 63.77B | 72.00B | 80.59B | 104.84B | 144.45B | 195.30B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 174.40B | 162.71B | 181.88B | 172.45B | 177.32B | 208.70B |
| Cash & ST investments | 41.55B | 18.93B | 32.58B | 26.96B | 21.63B | 44.98B |
| Inventory | 42.85B | 45.65B | 47.50B | 49.62B | 51.35B | 51.35B |
| Total assets | 489.16B | 482.15B | 512.29B | 542.90B | 559.22B | 594.94B |
| Total current liabilities | 236.12B | 207.52B | 234.36B | 215.66B | 225.16B | 239.08B |
| Short-term debt | 22.41B | 11.96B | 12.03B | 12.02B | 27.21B | 18.33B |
| Long-term debt | 96.31B | 87.31B | 89.18B | 111.71B | 119.17B | 121.79B |
| Total liabilities | 350,622,000,000.00 | 314,087,000,000.00 | 342,392,000,000.00 | 348,855,000,000.00 | 356,156,000,000.00 | 373,664,000,000.00 |
| Total equity | 138.54B | 168.07B | 169.90B | 194.05B | 203.07B | 221.28B |
| Retained earnings | 137.32B | 164.45B | 168.53B | 195.30B | 206.42B | 224.16B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 44.62B | 46.78B | 51.95B | 55.00B | 78.89B | 108.91B | 120.97B | 119.10B |
| Depreciation & amortization | 3.93B | 5.66B | 5.75B | 6.03B | 7.36B | 9.41B | 19.11B | 21.98B |
| Free cash flow | 32.21B | 35.55B | 29.87B | 47.62B | 64.13B | 70.01B | 69.66B | 28.99B |
| Dividends paid | -19.05B | -19.41B | -20.12B | -21.52B | -25.30B | -31.77B | -44.14B | -51.76B |
| Stock buybacks / issuance | -15.57B | -15.33B | -16.86B | -19.45B | -24.09B | -29.92B | -20.18B | -1.39B |
| Ending cash balance | 15.63B | 15.41B | 12.23B | 10.72B | 12.65B | 14.39B | 15.66B | 26.46B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 24.73B | 41.77B | 44.98B | 7.62B | 24.08B | -- |
| Depreciation & amortization | 3.83B | 4.83B | 7.76B | 5.56B | 3.54B | -- |
| Free cash flow | 10.14B | 25.50B | 29.56B | -36.22B | 12.05B | -- |
| Dividends paid | -35.27B | 174.00M | -16.66B | 0 | -35.31B | -- |
| Stock buybacks / issuance | -1.39B | 0 | 0 | 0 | -2.40B | -- |
| Ending cash balance | 38.94B | 18.44B | 32.08B | 26.46B | 21.13B | -- |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE % | 76.00 | 71.19 | 69.70 | 71.24 | 72.00 | 88.07 | 80.78 | 60.70 |
| ROA % | 36.25 | 32.96 | 31.15 | 28.14 | 25.48 | 30.12 | 25.89 | 20.31 |
| ROIC % | 74.44 | 66.55 | 62.14 | 55.89 | 53.84 | 68.57 | 53.09 | 36.67 |
| 5-year avg ROE % | 76.45 | 77.90 | 75.86 | 73.67 | 72.03 | 74.44 | 76.36 | 74.56 |
| EBIT margin % | 42.65 | 39.97 | 42.16 | 42.17 | 39.24 | 45.30 | 44.36 | 43.60 |
| FCF / sales % | 28.80 | 29.14 | 23.53 | 33.82 | 36.24 | 30.14 | 23.99 | 9.38 |
| Current ratio | 1.09 | 1.06 | 0.94 | 0.86 | 0.89 | 0.82 | 0.74 | 0.80 |
| Quick ratio | 0.79 | 0.76 | 0.64 | 0.65 | 0.67 | 0.62 | 0.53 | 0.54 |
| Debt / assets | 0.99 | 7.78 | 16.35 | 37.66 | 30.88 | 25.34 | 71.64 | 67.49 |
| LT debt / equity | -- | 5.22 | 4.57 | 18.32 | 29.13 | 19.26 | 62.50 | 61.29 |
| Interest coverage | 561.18 | 221.70 | 137.23 | 205.43 | 183.70 | 194.13 | 78.56 | 32.03 |
| Revenue CAGR (3Y) % | 1.19 | 2.97 | 4.36 | 7.98 | 13.19 | 22.31 | 27.29 | 20.43 |
| Net income CAGR (3Y) % | 3.48 | 0.89 | 3.39 | 7.33 | 12.54 | 25.70 | 28.35 | 22.65 |
| FCF CAGR (3Y) % | 0.34 | -3.89 | -2.79 | 13.92 | 21.73 | 32.84 | 13.52 | -23.26 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE % | 88.12 | 79.17 | 71.46 | 60.70 | 71.40 | 59.82 |
| ROA % | 26.55 | 26.09 | 22.81 | 20.31 | 23.27 | 21.62 |
| ROIC % | 55.29 | 51.09 | 46.05 | 36.67 | 39.85 | 36.83 |
| 5-year avg ROE % | -- | -- | -- | -- | -- | -- |
| EBIT margin % | 45.21 | 47.74 | 44.33 | 43.60 | 48.26 | 44.87 |
| FCF / sales % | 24.53 | 19.75 | 19.31 | 9.38 | 9.42 | 14.51 |
| Current ratio | 0.74 | 0.78 | 0.78 | 0.80 | 0.79 | 0.87 |
| Quick ratio | 0.54 | 0.50 | 0.53 | 0.54 | 0.54 | 0.64 |
| Debt / assets | 85.70 | 59.06 | 59.57 | 67.49 | 72.09 | 63.33 |
| LT debt / equity | 69.52 | 51.95 | 52.49 | 61.29 | 58.69 | 55.04 |
| Interest coverage | 28.86 | 18.28 | 17.49 | 32.03 | 62.70 | -158.09 |
| Revenue CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Obesity and Diabetes care93.75%
Rare Disease6.25%
Quote time 2026-09-04 20:02:22
For reference only, not investment advice.